Multi-laboratory evaluation of the Illumina iSeq platform for whole genome sequencing of Salmonella, Escherichia coli and Listeria.

There is a growing need for public health and veterinary laboratories to perform whole genome sequencing (WGS) for monitoring antimicrobial resistance (AMR) and protecting the safety of people and animals. With the availability of smaller and more affordable sequencing platforms coupled with well-defined bioinformatic protocols, the technological capability to incorporate this technique for real-time surveillance and genomic epidemiology has greatly expanded. There is a need, however, to ensure that data are of high quality. The goal of this study was to assess the utility of a small benchtop sequencing platform using a multi-laboratory verification approach. Thirteen laboratories were provided the same equipment, reagents, protocols and bacterial reference strains. The Illumina DNA Prep and Nextera XT library preparation kits were compared, and 2×150 bp iSeq i100 chemistry was used for sequencing. Analyses comparing the sequences produced from this study with closed genomes from the provided strains were performed using open-source programs. A detailed, step-by-step protocol is publicly available via protocols.io (https://www.protocols.io/view/iseq-bacterial-wgs-protocol-bij8kcrw). The throughput for this method is approximately 4-6 bacterial isolates per sequencing run (20-26 Mb total load). The Illumina DNA Prep library preparation kit produced high-quality assemblies and nearly complete AMR gene annotations. The Prep method produced more consistent coverage compared to XT, and when coverage benchmarks were met, nearly all AMR, virulence and subtyping gene targets were correctly identified. Because it reduces the technical and financial barriers to generating WGS data, the iSeq platform is a viable option for small laboratories interested in genomic surveillance of microbial pathogens.

Histopathologic Lesion Scoring and Histomorphometric Methods for Measuring Vaccine Reactions in the Trachea of Broiler Chickens.

Severity of the tracheal histologic inflammatory response induced in broilers by ocular inoculation of two infectious bronchitis (IBV) and three Newcastle disease virus (NDV) commercial vaccines were evaluated. The vaccine was delivered by eye drop with a coarse spray to day-old chicks. The vaccines were given individually or in various combinations and were evaluated relative to nonvaccinated controls. Evaluations were performed on postvaccination (PV) days 7 and 14. Histologic endpoints included semiquantitative severity scoring of inflammatory components and quantitative morphometric determinations of inflammatory cell concentration, mucosal thickness, and percentage of ciliated mucosal surface. Strong positive correlations were observed between routine severity scoring and morphometric inflammatory parameters, whereas a negative correlation was present between inflammation severity and the percentage of mucosal ciliation. Variable, sometimes extensive, and often statistically significant differences in inflammatory responses were observed between the various vaccines. One IBV Massachusetts strain vaccine (IBV-A) produced the greatest overall inflammatory response when given alone or in combination with the NDV vaccines. Enhancement of tracheitis was seen on PV day 14 by covaccination of IBV-A with the NDV vaccines, but not by covaccination of another IBV Massachusetts strain vaccine (IBV-B) with NDV. Reduction in cilia percentage was observed for all vaccine groups relative to controls on PV day 7. However, although reactive cilia regeneration occurred on PV day 14 for most vaccine groups, a cilia regenerative response was not apparent for individual or NDV combination vaccination for IBV-A. The study also demonstrates that substantial microscopic trachea pathology may be present in vaccinated birds not exhibiting apparent clinical respiratory signs.

Artículo regular­Métodos de calificación de lesiones histológicas e histomorfométricos para medir las reacciones a las vacunas en la tráquea de pollos de engorde. Se evaluó la gravedad de la respuesta inflamatoria histológica traqueal en pollos de engorde inducida mediante la inoculación ocular de dos vacunas comerciales contra la bronquitis infecciosa (IBV) y tres vacunas del virus de la enfermedad de Newcastle (NDV). Las vacunas se administraron mediante aplicación ocular a pollitos de un día de edad. Las vacunas se administraron individualmente o en varias combinaciones y se evaluaron en relación con los controles no vacunados. Las evaluaciones se realizaron en los días 7 y 14 después de la vacunación (PV). Los criterios de valoración histológicos incluyeron puntuación semicuantitativa de la severidad de los componentes inflamatorios y determinaciones morfométricas cuantitativas de la concentración de células inflamatorias, el grosor de la mucosa y el porcentaje de superficie de la mucosa con cilios. Se observaron fuertes correlaciones positivas entre la puntuación rutinaria de severidad y los parámetros morfométricos inflamatorios, mientras que se observó una correlación negativa entre la severidad de la inflamación y el porcentaje de la superficie con cilios en la mucosa. Se observaron diferencias variables, a veces extensas y a menudo estadísticamente significativas en las respuestas inflamatorias entre las diversas vacunas. Una vacuna de la cepa de Massachusetts del virus de la bronquitis infecciosa (IBV-A) produjo la mayor respuesta inflamatoria general cuando se administró sola o en combinación con las vacunas de Newcastle. Se observó un aumento de la traqueítis en el día 14 después de la vacunación mediante la vacunación simultánea de la vacuna de bronquitis infecciosa A con las vacunas de Newcastle, pero no mediante la vacunación simultánea de la otra vacuna de la cepa Massachusetts (IBV-B) con Newcastle. Se observó una reducción en el porcentaje de los cilios para todos los grupos vacunados en comparación con los controles en el día siete después de la vacunación. Sin embargo, aunque la regeneración de cilios reactivos ocurrió en el día 14 después de la vacunación para la mayoría de los grupos vacunados, no fue evidente una respuesta de regeneración de cilios para la vacunación individual o combinada de Newcastle con la vacuna de bronquitis infecciosa Massachusetts A. El estudio también demuestra que puede estar presente una patología microscópica sustancial de la tráquea en aves vacunadas que no presentan signos respiratorios clínicos aparentes.

Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.

To increase treatment efficiency for glioblastoma, we have developed a system to selectively deliver chemotherapeutic doxorubicin (Dox) to Glioblastoma (GBM) tumors. This carrier is based on elastin-like polypeptide (ELP), which is soluble at physiological temperatures but undergoes a phase transition and accumulates at tumor sites with externally applied, mild (40-41 °C) hyperthermia. The CPP-ELP-Dox conjugate consists of a cell penetrating peptide (CPP), which facilitates transcytosis through the blood brain barrier and cell entry, and a 6-maleimidocaproyl hydrazone derivative of doxorubicin at the C-terminus of ELP. The acid-sensitive hydrazone linker ensures release of Dox in the lysosomes/endosomes after cellular uptake of the drug conjugate. We have shown that CPP-ELP-Dox effectively inhibits cell proliferation in three GBM cell lines. Both the free drug and CPP-ELP-Dox conjugate exhibited similar in vitro cytotoxicity, although their subcellular localization was considerably different. The Dox conjugate was mainly dispersed in the cytoplasm, while free drug had partial nuclear accumulation in addition to cytoplasmic distribution. The intracellular Dox concentration was increased in the CPP-ELP-Dox cells compared to that in the cells treated with free Dox, which positively correlates with cytotoxic activity. In summary, our findings demonstrate that CPP-ELP-Dox effectively kills GBM cells. Development of such a drug carrier has the potential to greatly improve current therapeutic approaches for GBM by increasing the specificity and efficacy of treatment and reducing cytotoxicity in normal tissues.